Drug application
NEUTREXIN (TRIMETREXATE GLUCURONATE)
Drugs@FDA NDA 020326 · MEDIMMUNE ONCOLOGY
Key facts
| Drug name | NEUTREXIN |
|---|---|
| Active ingredients | TRIMETREXATE GLUCURONATE |
| Application type | NDA |
| Application number | 020326 |
| Company | MEDIMMUNE ONCOLOGY |
| Dosage forms | INJECTABLE, INJECTION |
| Strength | EQ 25MG BASE/VIAL |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 1 - New Molecular Entity |
| Latest submission status date | Dec 17, 1993 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: